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We have been investigating cardiovascular cell differentiation and
regeneration using pluripotent stem (ES/iPS) cells. We established a
mouse ES/iPS cell differentiation system for cardiovascular cells using
Flk1+ cells as common progenitors (Nature, 2000; Circulation, 2008).
Based on this system, we are performing broad researches from basic
studies for cell differentiation to applied studies for cardiac regeneration.
I. Basic studies for cell differentiation: we recently succeeded in demon-
strating differentiation stage-speciﬁc diverse roles of cyclic AMP (cAMP)/
protein kinase A (PKA) signaling during vascular cell differentiation.
1) From pluripotent stage to mesoderm, PKA accelerated differentiation
timing with epigenetic silencing of pluripotent genes through methyl-
transferase G9a (Cell Stem Cell, 2012). 2) During endothelial cell (EC)
differentiation from mesoderm, PKA increased vascular endothelial
growth factor (VEGF) receptor-2 and neuropilin1 expression in vascular
progenitors, which enhanced the progenitor sensitivity to VEGF and EC
differentiation (Blood, 2009). 3) That was mediated by direct transcrip-
tional cascade from cAMP-responsive element binding protein, Etv2
transcription factor, to VEGF receptors (Stem Cells, 2012a). 4) Kappa
opioid receptor signaling was a novel endogenous inhibitor for PKA and
EC differentiation (Blood, 2011). 5) cAMP signal induced dual activation
of Notch and beta-catenin and induced arterial speciﬁcation in ECs
(J Cell Biol, 2010). II. Chemical biological approach: We found that an
immunosuppressant, cyclosporin-A (CSA), showed a novel effect specif-
ically acting onmesoderm cells to drastically increase cardiac progenitors
as well as cardiomyocytes (Biochem Biophys Res Commun, 2009).
Applying this system, we screened small molecules and found several
novel compounds enhancing cardiomyocyte differentiation and prolifer-
ation. These ﬁndings would contribute to discovery for cardiac regener-
ative drugs and efﬁcient induction of cardiac cells fromES/iPS cells. III. Cell
therapy: We are also examining cell transplantation methods using
the cell sheet technology (Shimizu, Curr Pharm Des, 2009) for cardiac
regeneration. Combining our cardiovascular differentiation system and
cell sheet technology, we set out to reconstitute cardiac tissue re-
assembled with deﬁned cardiovascular populations, and examined the
effect of the cardiac tissue sheet following transplantation. We observed
that cardiac tissue sheet transplantation to rat myocardial infarction
model signiﬁcantly improved systolic function accompanied by neovas-
cularization (Stem Cells, 2012b). We extended these strategies to human
iPS cells. We recently succeeded in developing efﬁcient cardiomyocyte
differentiation and puriﬁcation methods in human iPS cells (PLoS One,
2011a, 2011b). Now we are examining effects of human iPS cell-derived
cardiac sheet transplantation in rat and porcine myocardial infarction
models. I would like to show and discuss our studies with stem cell,
chemical, and vascular biology.
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